Abstract:Background: Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases that play a key role in both physiological and pathological tissue degradation. MMPs have reportedly shown great potentials in the degradation of the Extracellular Matrix (ECM), have shown great potentials in targeting bioactive and imaging agents in cancer treatment. MMPs could provoke Epithelial to Mesenchymal Transition (EMT) of cancer cells and manipulate their signaling, adhesion, migration and invasion to promote cancer cell aggressiveness. Therefore, targeting and particularly inhibiting MMPs within the tumor microenvironment is an effective strategy for cancer treatment. Based on this idea, different MMP inhibitors (MMPIs) have been developed to manipulate the tumor microenvironment towards conditions appropriate for the actions of antitumor agents. Studies are ongoing to improve the selectivity and specificity of MMPIs. Structural optimization has facilitated the discovery of selective inhibitors of the MMPs. However, so far no selective inhibitor for MMP-7 has been proposed. Aims: This study aims to comprehensively review the potentials and advances in applications of MMPs particularly MMP-7 in targeted cancer treatment approaches with the main focus on targeted drug delivery. Different targeting strategies for manipulating and inhibiting MMPs for the treatment of cancer are discussed. MMPs are upregulated at all stages of expression in cancers. Different MMP subtypes have shown significant targeting applicability at the genetic, protein, and activity levels in both physiological and pathophysiological conditions in a variety of cancers. The expression of MMPs significantly increases at advanced cancer stages, which can be used for controlled release in cancers in advance stages. Methods: Moreover, this study presents the synthesis and characteristics of a new and highly selective inhibitor against MMP-7 and discusses its applications in targeted drug delivery systems for therapeutics and diagnostics modalities. Results: Our findings showed that the structure of the inhibitor P3’ side chains play the crucial role in developing an optimized MMP-7 inhibitor with high selectivity and significant degradation activities against ECM. Conclusion: Optimized NDC can serve as a highly potent and selective inhibitor against MMP-7 following screening and optimization of the P3’ side chains, with a Ki of 38.6 nM and an inhibitory selectivity of 575 of MMP-7 over MMP-1.

Matrix Metalloproteinase Inhibitors (mmpis) As Attractive Therapeutic Targets: Recent Progress and Current Challenges

MMP Enzyme in Tumor Micro-environment: A Promising Target for Nano-medicine Delivery

Progress in Development of Matrix Metalloproteinase Inhibitors

An Updated Patent Therapeutic Agents Targeting Mmps

Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (Mmps)

Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.

Matrix Metalloproteinases As Novel Biomarker S and Potential Therapeutic Targets in Human Cancer

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents

Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments

Novel Drug Discovery Approaches for MMP-13 Inhibitors in the Treatment of Osteoarthritis

Matrix Metalloproteinases (mmps) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor Against Matrix Metalloproteinase-7

Matrix Metalloproteinase Inhibitors As Therapy for Inflammatory and Vascular Diseases.

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics

Matrix metalloproteinases involvement in pathologic conditions

Matrix Metalloproteinases: New Targets in Cancer Therapy

Advances in Assays of Matrix Metalloproteinases (mmps) and Their Inhibitors

Advances in Matrix Metalloproteinase Inhibitors Based on Pyrrolidine Scaffold

MMP-Responsive 'Smart' Drug Delivery and Tumor Targeting

Targeting Matrix Metalloproteinases by E3 Ubiquitin Ligases As a Way to Regulate the Tumor Microenvironment for Cancer Therapy.

Matrix Metalloproteases-Responsive Nanomaterials for Tumor Targeting Diagnosis and Treatment.

Matrix Metalloproteinases in Tumorigenesis: an Evolving Paradigm